October 2005 Archives
New MultiCell/Thomas Jefferson University Research Collaboration to Evaluate Cell Lines for Hepatitis C Treatment
LINCOLN, R.I., Oct. 20, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), announced today that the Company has entered into a research collaboration with Thomas Jefferson University, Philadelphia's premier medical and health sciences university, to evaluate the Company's immortalized human hepatocytes as model systems to identify new drugs to treat hepatitis C viral (HCV) infection.
...Posted on October 23, 2005 03:53 PM | Comments (0)
MultiCell Enters into a Joint Venture with Living Cell Technologies
MultiCell Enters into a Joint Venture with Living Cell Technologies to Develop Adult Liver Cell Technologies for Drug Discovery, Protein Production and Therapeutic Clinical Applications
LINCOLN, RI – Tuesday, October 4, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery and Living Cell Technologies Limited (LCT), a developer of injectable live cell therapy products to treat life threatening diseases, announced today that the parties have entered into a joint venture to develop therapeutic liver cell applications.
...Continue reading "MultiCell Enters into a Joint Venture with Living Cell Technologies"
Posted on October 23, 2005 03:10 PM | Comments (0)
Adult Stem Cells Aid Recovery In Animal Model Of Cerebral Palsy
Researchers report that a recent study, run at Medical College of Georgia, shows the adult stem cell therapy quickly and significantly improving the recovery of motor function in an animal model for the ischemic brain injury that occurs in about 10 percent of babies with cerebral palsy.
Co-authors on the study include Dr. David Hess, chair of the MCG Department of Neurology; Dr. Lin Xu, research scientist; Drs. Noriyuki Matsaukawa, Guolong Yu, Takao Yasuhara and Koichi Hara, postdoctoral fellows; and Athersys scientists Robert Mays, Jim Kovach and Robert Deans.
...Continue reading "Adult Stem Cells Aid Recovery In Animal Model Of Cerebral Palsy"
Posted on October 21, 2005 06:43 PM | Comments (0)
Chemicon Announces Agreement with Stem Cell Sciences for Exclusive Manufacturing and Marketing of Novel
Chemicon Announces Agreement with Stem Cell Sciences for Exclusive Manufacturing and Marketing of Novel
ATLANTA, GA and EDINBURGH, SCOTLAND – October 6 , 2005 – Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences Holdings LTD (LSE:STEM), have signed an exclusive agreement to manufacture and market novel patent-protected embryonic stem (ES) cell media for the research market.
Under the terms of this agreement, SCS will transfer the patented technology and expertise to Chemicon to allow it to manufacture a fully formulated cell culture media that Chemicon will exclusively market worldwide.
...Posted on October 21, 2005 01:50 PM | Comments (0)
Serologicals Corporation Schedules Third Quarter Earnings Release And Conference Call
ATLANTA, GA – October 17, 2005 – Serologicals Corporation (NASDAQ: SERO) announced today that it will release its third quarter earnings on Thursday, October 27, 2005 after the close of regular trading hours, and then host a conference call on Friday, October 28, 2005 at 11:00 a.m. (ET) to review the results.
The conference call dial-in number is 888-396-2384, International dial-in 617-847-8711, confirmation code 13958054.
...Posted on October 21, 2005 01:41 PM | Comments (0)
Chemokine Therapeutics Expands Protection of Core Anti-Cancer Technology with Issuance of New U.S. Patent
Vancouver, BC (October 5, 2005) – Chemokine Therapeutics Corp. (the Company) (OTCBB: CHKT; TSX: CTI), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, cardiovascular, and infectious diseases, today announced that it has been granted U.S.
Patent No. 6,946,445 relating to a broad range of composition of matter claims, which include claims that cover its lead anti-cancer compound, CTCE-9908, among others. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.
...Posted on October 21, 2005 01:37 PM | Comments (0)
Hwang Woo-suk Seeks AIDS Cure from Stem Cells
Scientists led by Korea's Dr. Hwang Woo-suk are seeking ways to fight Aids using human stem cells, according to Gerald Schatten, a close collaborator of Korea’s cloning pioneer. The team is studying the viability of repairing the body’s immune system by cloning HIV-resistant cells.
...Continue reading "Hwang Woo-suk Seeks AIDS Cure from Stem Cells"
Posted on October 18, 2005 06:36 PM | Comments (0)
Aastrom Biosciences Receives Phase II NIH Grant to Support Further Development of its Proprietary Stem Cell Manufacturing Systems
ANN ARBOR, Mich., October 18, 2005 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. today announced that it has received a Small Business Innovation Research Phase II grant from the National Institutes of Health (NIH) entitled "Clinical Human Cell Production System for Broad Use". The two-year Phase II grant from the National Institute of Nursing Research (NINR) totals $798,000, of which $270,000 has been awarded for the first year of this study. This Phase II grant follows a Phase I grant awarded to Aastrom in 2003 by the NIH's National Institute of Biomedical Imaging and Bioengineering.
...Posted on October 18, 2005 06:29 PM | Comments (0)
Bone Marrow Stem Cell Transplants Improve Heart Function
An encouraging study presented at the Cardiovascular Research Foundation’s (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium has shown that transplantation of bone marrow stem cells into the heart improves heart function and blood flow in heart attack patients for up to six months. Among other applications, scientists are currently investigating these stem cells and their potential in repairing damage or loss to cardiac cells and tissues due to heart attacks or other heart conditions.
Bone marrow mononuclear (stem) cells, or BMMCs, are derived from the soft, sponge-like marrow found inside bones, and can develop into tissue or new blood vessels. Patients in this study were treated with stem cells extracted from their own bone marrow.
...Continue reading "Bone Marrow Stem Cell Transplants Improve Heart Function"
Posted on October 18, 2005 06:22 PM | Comments (0)
AnorMED to Seek Conditional Marketing Authorization in Europe for MOZOBIL, a New Stem Cell Mobilizer
Clinical Results from MOZOBIL Compassionate Use Program in Stem Cell Transplant Accepted for Oral Presentation at the American Society of Hematology Meeting in Atlanta, Georgia
VANCOUVER, British Columbia, October 18, 2005 /PRNewswire-FirstCall/ - AnorMED Inc. announced today that it will seek a Conditional Marketing Authorization (CMA) for MOZOBIL (AMD3100, Plerixafor) in Europe in early 2007. The Company also plans to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMEA) based on the Phase III program currently ongoing in the U.S.
...Posted on October 18, 2005 06:19 PM | Comments (0)
U.S. BioDefense Receives First Stem Cell Line and Extends Agreement With University of British Columbia
U.S. BioDefense (OTC BB: UBDE) is pleased to announce today that it has received its first stem cell line as a part of an agreement with the University of British Columbia.
The company will begin evaluation of the neural crest stem cell line before beginning production of a commercial line which will be available for research use by Universities and other biotech companies. We will also be evaluating the utilization of this line for human transplantation and in collaboration with the FDA; we will investigate whether further development of this cell line will make it appropriate for the treatment of brain neurodegeneration and spinal cord repair.
...Posted on October 17, 2005 06:37 PM | Comments (0)
Aastrom Biosciences' Tissue Repair Cells Used In New Clinical Trial For Regeneration Of Vascular Tissue In Diabetic Patients
Novel Treatment Utilizes Company's Adult Bone Marrow Stem Cell Product
Ann Arbor, Michigan, October 6, 2005 – Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that the first clinical trial utilizing Aastrom's proprietary Tissue Repair Cells (TRCs) to treat limb ischemia in diabetic patients has been initiated at the Diabetes Center at the Heart and Diabetes Center North Rhine-Westphalia (Diabetes Center) located in Bad Oeynhausen, Germany.
...Posted on October 17, 2005 06:30 PM | Comments (0)
Chemicon International Announces Agreement with Axordia for Exclusive Co-Development of Human Embryonic Stem Cell Antibody Markers
ATLANTA, GA and SHEFFIELD, UK – September 30, 2005 – Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Axordia Ltd. have signed an exclusive agreement to co-develop new antibody markers from Axordia's proprietary human embryonic stem (ES) cell lines.
Under the terms of this agreement, Axordia will contribute proprietary expertise and materials for antibody generation and antibody characterization and Chemicon will commercialize the new antibody research tools arising from this collaboration.
...Posted on October 17, 2005 06:17 PM | Comments (0)
Alan L. Rubino Elected To Aastrom Biosciences' Board Of Directors
Ann Arbor, Michigan, September 30, 2005 - Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Alan L. Rubino, a Principal with Watchung Partners, has been elected to the Company's Board of Directors. He will serve as a Class III Director whose term expires at Aastrom's Annual Meeting of Shareholders in 2006. Mr. Rubino has been appointed to the Board's Audit Committee.
"We are excited to welcome Alan Rubino to our Board, as he will be an important industry resource for our Company," said R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom.
...Continue reading "Alan L. Rubino Elected To Aastrom Biosciences' Board Of Directors"
Posted on October 17, 2005 06:06 PM | Comments (0)
Aastrom Biosciences, Inc. Reports Fourth Quarter 2005 Financial Results
Ann Arbor, Michigan, September 8, 2005 - Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the fourth quarter and fiscal year ended June 30, 2005. The Company also reported significant clinical and operational achievements of the last quarter and fiscal year. For the quarter ended June 30, 2005, these achievements included:
• Clinical progress:
Announced positive results from its feasibility clinical trial conducted in Barcelona, Spain to evaluate the use of Aastrom's Tissue Repair Cells (TRCs) for the treatment of severe long bone non-union fractures. All of the patients treated with TRCs, an autologous bone marrow-derived cell product, exhibited clinical and functional healing, with 5 of 6 treatments showing bone regeneration at the fracture site as determined by radiographic imaging by 6 months. The results were notable in that each patient had failed prior treatment with standard of care methodologies and had a poor prognosis for healing. ...Continue reading "Aastrom Biosciences, Inc. Reports Fourth Quarter 2005 Financial Results"
Posted on October 17, 2005 06:00 PM | Comments (0)
Stem Cell Therapeutics Corp. and Medicon A/S Announce the Submission of Proposed NTx(TM)-265 European Phase I Clinical Trial Study to the Danish Regulatory Agency
CALGARY, Oct. 3 /CNW/ - Stem Cell Therapeutics Corp. ("SCT") announced today that Medicon A/S ("Medicon") of Birkerod, Denmark has submitted a Phase 1 clinical trial study protocol to the Danish Regulatory Agency on behalf of SCT for its NTx(TM)-265 program for the treatment of stroke. Stroke, the third leading cause of death in the United States and second worldwide, has an incidence of 700,000 patients in the U.S. each year.
With currently available therapies, less than 4% of stroke patients are treated with interventional drugs. The American Heart Association estimated the economic costs in the US at $54B in 2004.
...Posted on October 17, 2005 05:58 PM | Comments (0)
StemCells, Inc. Moves to NASDAQ National Market
PALO ALTO, Calif., (September 30, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced that the Nasdaq Stock Market has approved its application to transfer the listing of its common stock to the National Market from the Capital Market.
...Continue reading "StemCells, Inc. Moves to NASDAQ National Market"
Posted on October 17, 2005 05:55 PM | Comments (0)
New Life Scientific Offers Newly Expanded Services
FREEHOLD, N.J., Sept. 29, 2005 - New Life Scientific, Inc. (OTCBB:NWLF) announced Thursday it will expand its services to offer market research and regulatory services through Pharma Trials International, Inc., its wholly owned subsidiary.
Pharma Trials International, Inc. will expand its services to offer market research and regulatory services, market needs, market trends, new government regulations regarding the importation of drugs, statistics and market analysis including the sale of drugs in certain therapeutic categories.
...Continue reading "New Life Scientific Offers Newly Expanded Services"
Posted on October 17, 2005 05:50 PM | Comments (0)
Stem Cell Therapeutics Corp. and Medicon A/S Sign Contract to Perform Phase I Clinical Study
CALGARY, Sept. 29 /CNW/ - Stem Cell Therapeutics Corp. ("SCT") announced today that they have signed a contract with Medicon A/S ("Medicon") of Birkerod, Denmark to perform a Phase I clinical trial.
The contract encompasses submission of SCT's Phase I clinical trial protocol, screening, conduct and reporting of trial results. This agreement follows the successful clinical trial feasibility assessment and positive regulatory response that Medicon and SCT have achieved to date.
...Posted on October 17, 2005 05:32 PM | Comments (0)
Stem Cell Therapy International, Inc. Announces Symbol Change to "SCII"
TAMPA, FL, Oct 14, 2005 - Stem Cell Therapy International, Inc. (Other OTC:ATYD.PK), a pioneer in the field of research and development of stem cell transplantation (SCT) therapy and regenerative medicine, announced today that it has changed its stock symbol to OTCBB: SCII.OB and will begin trading under the new stock symbol effective immediately.
...Continue reading "Stem Cell Therapy International, Inc. Announces Symbol Change to "SCII""
Posted on October 17, 2005 05:09 PM | Comments (0)
University of Minnesota Researchers Use Stem Cells to Kill Cancer Cells
Stem cell researchers at the University of Minnesota have used human embryonic stem cells to create cancer-killing cells. This latest discovery paves the way for future treatments for various types of cancers. The results of this research is to be published in the October 15 issue of the Journal of Immunology.
...Continue reading "University of Minnesota Researchers Use Stem Cells to Kill Cancer Cells"
Posted on October 12, 2005 05:48 PM | Comments (0)
CRYO-CELL International Reports Third Quarter 2005 Results
Oldsmar, FL – October 4, 2005 - CRYO-CELL International, Inc. (OTC BBl:CCEL) (the "Company"), the world’s largest private cord blood bank, announced today financial results for the third quarter ended August 31, 2005.
Consolidated revenues for the quarter were approximately $3.8 million, up 17% from approximately $3.2 million for the third quarter ended August 31, 2004.
...Continue reading " CRYO-CELL International Reports Third Quarter 2005 Results"
Posted on October 7, 2005 05:04 PM | Comments (0)
Cord Blood America Featured in AGORA Webcast
LOS ANGELES, Oct. 3, 2005 - Cord Blood America, Inc. (OTCBB:CBAI), an umbilical cord blood stem cell preservation company, is pleased to announce that it has been featured in a Webcast by AGORA Investor Relations.
...
Continue reading "Cord Blood America Featured in AGORA Webcast"
Posted on October 7, 2005 04:58 PM | Comments (0)
Immortalization of Human Cord Blood Progenitor Cells: New Research From George Washington University Medical Center
DURHAM, N.C., Sept. 30 - The ability to derive adult stem cell lines from different human tissues would provide an adjunct to human embryonic stem cells (hESCs) for biomedical research.
A forthcoming article in the journal Stem Cells by scientists at The George Washington University Medical Center in Washington, D.C., describes a method that may ultimately lead to this goal in the case of the hematopoietic (blood-forming) system.
...Posted on October 7, 2005 04:42 PM | Comments (0)
First Public Cord Blood Bank Opens in Singapore
Southeast Asia's first public cord blood bank of international standards was officially opened at the KK Women's and Children's Hospital on Wednesday.
The Singapore Cord Blood Bank hopes to save some 80 Singaporeans with blood diseases every year, as well as patients from neighbouring countries.
...Continue reading "First Public Cord Blood Bank Opens in Singapore"
Posted on October 4, 2005 06:30 PM | Comments (0)
MEPs Challenge EU Stem Cell Research
In the context of the proposed new EU framework programme for research (FP7), a group of members of the Parliament (MEPs) are calling for the Community to stop the EU funding for human stem cell research.
As some EU countries ban stem cell research, the MEPs say it is wrong that taxpayers money from those countries is used to fund the research in others.
They thus propose to leave this type of research to the member states and national funding.
...Continue reading "MEPs Challenge EU Stem Cell Research"
Posted on October 4, 2005 06:24 PM | Comments (0)
New Life Scientific Signs Letter of Intent With CureLab, Inc
New Life Scientific Signs Letter of Intent With CureLab, Inc. for Long Term Agreement of Joint Development and Marketing Plan
FREEHOLD, N.J., Sep 23, 2005 - New Life Scientific, Inc. (OTCBB:NWLF) today announced the signing of a Letter of Intent with CureLab, Inc. for a long-term Joint Development and Marketing Plan (JDMP) of Cure Lab's pharmaceutical and biotech products.
...Continue reading "New Life Scientific Signs Letter of Intent With CureLab, Inc"
Posted on October 4, 2005 06:16 PM | Comments (0)
Adult Stem Cell Trial Approved by Royal Melbourne Hospital for Orthopaedic Use
MELBOURNE, Australia, Sept. 23 - Australian adult stem cell company, Mesoblast Limited (ASX: MSB), announced today approval to commence the first human orthopaedic trial of Mesoblast's specialist adult stem cell technology.
Approval from The Royal Melbourne Hospital's Human Research Ethics Committee is for a Pilot Trial of up to 10 patients suffering from non-union of long bone fractures, which affects up to two million people each year in developed countries around the world.
...Continue reading "Adult Stem Cell Trial Approved by Royal Melbourne Hospital for Orthopaedic Use"
Posted on October 4, 2005 06:08 PM | Comments (0)
Osiris Launches the Osteocel(R) Product Line
Bone repair product provides a much needed option for orthopedic surgery
BALTIMORE - Sept. 22, 2005 - Osiris Therapeutics, Inc. announced today that it has begun distribution of Osteocel a product indicated for the repair, replacement and/or reconstruction of bone defects.
Osteocel is an allogeneic bone matrix containing viable stem cells. In developing the product, Osiris leveraged its extensive experience in stem cell technology to offer an alternative to autograft in orthopedic procedures.
...Continue reading "Osiris Launches the Osteocel(R) Product Line"
Posted on October 4, 2005 06:02 PM | Comments (0)
New Life Scientific, Inc. and UTEK Corporation Announce Strategic Alliance Agreement
FREEHOLD, N.J. and PLANT CITY, Fla. - Sept. 22, 2005 - New Life Scientific, Inc. (OTCBB:NWLF), a company engaged in developing stem cell banks and stem cell treatment facilities, and UTEK Corporation (AMEX:UTK) (LSE-AIM:UTKA), an innovative technology transfer company, announced today the signing of a strategic alliance agreement.
Henry Val, President and Chief Executive Officer of New Life Scientific, Inc., said, "We are enthusiastic about forming a strategic alliance with UTEK Corporation which we believe will enable us to identify synergistic technology acquisition opportunities related to stem cell research."
...Posted on October 4, 2005 05:58 PM | Comments (0)
Cellerant Therapeutics Adds $9 Million to Series B Round for a Total of $25 Million
SAN CARLOS, Calif. - Sept. 22, 2005 - Cellerant Therapeutics, Inc. today announced that it has raised $9 million in a second closing of its Series B round, bringing the total to $25 million.
The first closing was led by Novel Bioventures, with the participation of Series A stockholders MPM Capital, Allen & Company LLC, and BD Ventures, and new investors CX Venture Group and Amgen founder George Rathmann. Participants in this second closing include Camelot Ventures, George Rathmann and Eminent Venture Capital Corp.
...Posted on October 4, 2005 05:54 PM | Comments (0)
Stem Cell Therapy International Engages the Cutler Law Group
TAMPA, Fla. - Sept. 22, 2005 - Stem Cell Therapy International, Inc., (ATYD), a company in the field of regenerative medicine that specializes in the treatment of patients with stem cell transplantation therapy as well as being a global supplier of biological solutions containing new lines of stem cell products, has retained the services of the Augusta, Georgia-based Cutler Law Group, a firm specializing in national and international securities law transactions.
...Continue reading "Stem Cell Therapy International Engages the Cutler Law Group"
Posted on October 4, 2005 05:46 PM | Comments (0)
Stem Cell Therapeutics Corp. to Present at BioContact Québec
CALGARY, Oct. 5 /CNW/ - Dr. Joseph Tucker, President and CEO of Stem Cell Therapeutics Corp. ("SCT"), will present a corporate update focusing on the clinical trial development of SCT's lead program, NTx(TM)-265, at BioContact Québec 2005.
More than 150 biopharmaceutical companies from Canada, the United States, Asia and Europe will be presenting at the partnership symposium to be held October 05-07, 2005 at the Château Frontenac in Quebec City.
...
Continue reading "Stem Cell Therapeutics Corp. to Present at BioContact Québec"
Posted on October 4, 2005 05:45 PM | Comments (0)
Vitro Signs Letter of Intent to Form Strategic Alliance With European Biotechnology Firm
AURORA, CO - 09/21/2005 - Vitro Diagnostics, Inc. (OTC BB: VODG), a biotechnology company, executed a binding letter of intent to form a broad-ranging strategic alliance with BioCare Europe headquartered in Rome, Italy.
The partnership includes various agreements with regard to commercialization of Vitro's stem cell lines for use in research and development and cross licenses to fertility drug technology and products owned by both Vitro and BioCare.
...Posted on October 4, 2005 05:38 PM | Comments (0)
Survivors of Stem Cell Transplant Report More Health Problems
Researchers from the Fred Hutchinson Cancer Center and the University of Washington have reported that adult long-term survivors of hematopoietic stem cell (SCT) transplants, mostly allogeneic, have more medical problems than the general population but have similar hospitalization rates to a control population.
The details of this report appeared in the September 20, 2005, issue of the Journal of Clinical Oncology .
...Continue reading "Survivors of Stem Cell Transplant Report More Health Problems"
Posted on October 4, 2005 05:34 PM | Comments (0)
U-M Launches Center For Stem Cell Biology
ANN ARBOR, Mich. — President Mary Sue Coleman announced on Sept. 19th, that the University of Michigan will expand its efforts in stem cell science with the creation of a new center for stem cell research, to be based at the Life Sciences Institute.
...Continue reading "U-M Launches Center For Stem Cell Biology"
Posted on October 4, 2005 05:29 PM | Comments (0)
Childrens Hospital Los Angeles Receives a Stand-Alone Stem Cell Training Grant from the California Institute for Regenerative Medicine
Other Grants Made to USC, Stanford, Cal Tech and UCLA, Among Other Institutions
LOS ANGELES, Sept. 12, 2005 - The Saban Research Institute of Childrens Hospital Los Angeles has received an initial three-year, $2.4 million stem cell training grant from the California Institute for Regenerative Medicine (CIRM), according to Donald B. Kohn, M.D., director of the Gene, Immune and Stem Cell Therapy Program at Childrens Hospital Los Angeles, and professor of pediatrics, molecular microbiology and Immunology at the Keck School of Medicine of the University of Southern California.
...Posted on October 4, 2005 05:18 PM | Comments (0)
U.S. BioDefense Receives First Stem Cell Line and Extends Agreement With University of British Columbia
CITY OF INDUSTRY, Calif., Sept. - U.S. BioDefense (OTC BB: UBDE) is pleased to announce today that it has received its first stem cell line as a part of an agreement with the University of British Columbia.
The company will begin evaluation of the neural crest stem cell line before beginning production of a commercial line which will be available for research use by Universities and other biotech companies.
...Posted on October 4, 2005 05:09 PM | Comments (0)
Stem Cell Therapy International Signs Exclusive License Agreement for the Supply of Stem Cells and Use of 26 Related Patents from the Institute of Cell Therapy In Kiev, Ukraine
TAMPA, Fla. - Sept. 19, 2005 - Stem Cell Therapy International, Inc. (OTC: ATYD) today announced that it has signed an exclusive global Licensing Agreement with the Institute of Cell Therapy (ICT) a biotechnology company incorporated and organized in Kiev, Ukraine, for the supply of stem cells and use of 26 related patents.
The agreement is in effect for a period of ten (10) years with an option to renew for another ten (10) and covers access to a worldwide territory for Stem Cell Therapy International, except for five countries, yet to be named.
...Posted on October 4, 2005 04:44 PM | Comments (0)
Stem Cell Therapy International Names Four Leading Scientists to Scientific Advisory Board
Advisory Board to Dramatically Expand Stem Cell Therapy International's Role in the Advancement and Application of Stem Cell Transplantation Therapy
TAMPA, Fla. - Sept. 28, 2005 - Stem Cell Therapy International (OTC:ATYD) today announced the appointment of four leading international scientists in the field of stem cell transplantation therapy to the company's working Scientific Advisory Board.
...Posted on October 3, 2005 04:48 PM | Comments (0)